Navigation Links
Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Date:3/10/2008

Company to host conference call Today, Monday, March 10, 2008 at 8:30am

NEW YORK, March 10 /PRNewswire-FirstCall/ -- On Friday, March 7, 2008, Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), announced top-line results from its SUN-MICRO Phase 3 clinical trial of Sulonex (sulodexide) for the treatment of diabetic nephropathy. The Company announced that this Phase 3 clinical trial failed to meet the primary objective of the study, which was to increase the proportion of patients that achieve therapeutic success at 6 months as compared to placebo over background therapy of maximal doses of ACE-inhibitors or ARBs. Therapeutic success was defined as (i) conversion from microalbuminuria to normoalbuminuria, as measured by albumin/creatinine ratio (ACR), with at least a 25% reduction in ACR relative to baseline ACR, or (ii) a 50% reduction in ACR relative to baseline ACR. In addition, in reviewing the mean changes in ACR over time, Sulonex and placebo appeared to be similar.

Michael S. Weiss, the Company's Chairman and Chief Executive Officer, commented, "We are all very disappointed with the outcome of this Study. While this represents the end of one chapter for Keryx, it is not the end of Keryx. Drug development is inherently risky and, accordingly, we have spent the last several years building what we believe to be a promising product portfolio in the event our lead drug failed. We plan to re-focus our primary efforts and resources on rapidly moving Zerenex forward for ESRD patients with hyperphosphatemia and Perifosine forward for cancer. Our goal is to have Perifosine in a pivotal program this year and be well into our Zerenex high- dose Phase 2 trial before the end of the year."

In order to participate in this morning's c
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
3. Keryx Biopharmaceuticals Announces Additions to Management Team
4. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
5. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
7. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
8. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
9. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
10. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009).... 6 ,, 3Q09 Corpor...enza(TM) E.U. Marketing Authorization to Astellas ...commercial readiness activities Expanded manageme...eting; and Director, Commercial Operations Appoin...udit Committee chairman , Upcoming 2009 Mil...
(Date:11/6/2009)...6 Intarcia Therapeutics, Inc. deli...OS® continuous delivery of exenatide) program... Annual Diabetes Technology Meeting in San Francis...in/prnh/20050301/SFTU126LOGO ) ,, Continuous ...wers Plasma Glucose, HbA1c and Reduces Weight in a...
(Date:11/5/2009).... 5 GenVec, Inc. (Nasdaq...r the third quarter ended September 30, 2009. GenV...share) for the three months ended September 30, 20...er share) in the comparable quarter of 2008. For t...net loss was $14.1 million ($0.15 per share), comp...
(Date:11/5/2009)...ewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bullet...cer, President and CEO of Imagenetix, will be pres...CRO Conference on Thursday, December 3rd, at 10:30...bout LD MICRO ,, LD MICRO is a by-invitation on...lued companies in the micro-cap space. Since 2002,...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2
... Cell Biosciences, Inc., a,provider of nanoproteo...today,announced the launch of its first kits for t...y(TM) 3000 Protein Analysis System. The new kits a...he MEK and ERK families, which,play critical roles...evelopers,have targeted signaling via MEK and ERK ...
...ed Decision Support in Diabetes Drug Therapy , , ...shown statistically significant associations of ce...y mass index (BMI) and edema (fluid retention) in ...pioglitazone and rosiglitazone. The study, co-auth...r Affiliate at The Hospital of Central Connecticut...
...ic, a division of Simbionix USA,Corporation (Simbi...ducts and,technology for training medical salespeo.... Williams joined the company as Sales Executive f...out of a new office located in,Grayslake, Illinois...rning technologies and medical,procedures. His pri...
Other Biology Technology:Cell Biosciences Introduces Kits for Oncoprotein Analysis 2Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study 2Glen C. Williams Joins eLearning Sales Team for Simbionix, Heading up Chicago Office 2
(Date:11/4/2009)...wire-FirstCall/ -- Aware, Inc. (Nasdaq: AWRE ), a...etrics software, today reported financial results ... ,, Michael Tzannes, Aware,s Chairman and Chief...nced an agreement to sell our DSL and home network...ductor company being spun out of Infineon. This t...
(Date:11/4/2009)...-FirstCall/ -- BIO-key International, Inc. (OTC Bu...etric identification software is showcasing donor ...nference being held at the New Orleans Convention ...de hands-on product demonstrations of its state-of...Also, at 5 PM on Monday, October 26, Peter Lux, ma...
(Date:11/4/2009)...swire/ -- GenVault Corporation (Carlsbad, CA) toda...oined its Board of Directors. Dr. Brody, the Irwi... is an acclaimed physician-scientist and universit.... Brody served as president of The Johns Hopkins U... of Engineering and the Institute of Medicine, and...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7BIO-key(R) International Exhibiting at AABB TXPO 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Equity Capital Management H1N1 Vaccines and Hard to Treat Diseases 28HTDS 29 57763 1Equity Capital Management H1N1 Vaccines and Hard to Treat Diseases 28HTDS 29 57763 2ANAVEX completes scale up manufacturing of ANAVEX 2 73 for Phase I Alzheimers disease clinical trials 5022 1ANAVEX completes scale up manufacturing of ANAVEX 2 73 for Phase I Alzheimers disease clinical trials 5022 2ANAVEX completes scale up manufacturing of ANAVEX 2 73 for Phase I Alzheimers disease clinical trials 5022 3Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors 14176 1Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors 14176 2Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors 14176 3Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors 14176 4
...new study explores the role of natural enemies, su... reproductive strategy in which hermaphroditic pla...ross-fertilization. The findings highlight the pos...ons. , Mating systems are a complex set of traits...ion structure, demography, and numerous environmen...
...a on soil quality and agriculture? How can soil he...xtent can biofuels help make America energy indepe...will be discussed at the International Annual Meet...op Science Society of America (CSSA), and Soil Sci...he Ernest N. Morial Convention Center in New Orlea...
...laug and Rob Horsch of the Gates Foundation will d...echnologies to feed the world to kick off the Inte...of Agronomy (ASA), Crop Science Society of America...) in New Orleans. They will speak on Sunday, Nov. ...on Riverside. , Horsch will present New Investmen...
Other Biology News:Predators and parasites may increase evolutionary stability 2Food and environmental sustainability focus of ASA-CSSA-SSSA Annual Meetings 2Norman Borlaug, Rob Horsch to keynote world hunger lecture 2
... with HRP conjugated rabbit polyclonal detection a... coating antibody. • BUF040A contains rab...ding between the coating and detection antibodies....ewly conjugated antibodies, to reconstitute lyophi...
...el piece, we can identify it using MALDI-TOF/TOF m...duce a mixture of peptides. The molecular weights ..., and the amino acid sequences of the top 10 peaks...ALDI-TOF/TOF. The masses and sequences will be use...
OmniSlide Heated Wash Module from Thermo Scientific
Factor Xa Protease from QIAGEN
Biology Products: